Liver Illness and Psoriatic Patients

Area of Science:

• Dermatology
• Hepatology
• Pharmacology

Background:

• Psoriasis affects 2% of the global population.
• Systemic treatments like methotrexate and cyclosporin can cause hepatotoxicity.
• Managing psoriasis patients with liver dysfunction presents a therapeutic challenge.

Purpose of the Study:

• To provide guidance for clinicians managing psoriatic patients with liver dysfunction.
• To review potential causes of liver injury in psoriasis patients undergoing systemic treatment.

Main Methods:

• A comprehensive literature search was conducted.
• Databases searched include PubMed, EMBASE, and Cochrane.
• Keywords included psoriasis, hepatotoxicity, drug toxicity, viral hepatitis, nonalcoholic fatty liver disease, cholestasis, and autoimmune liver diseases.

Main Results:

• Systemic psoriasis treatments carry risks of direct liver injury and immunosuppression-related liver issues.
• Hepatotoxicity can manifest as drug-induced liver injury, cholestasis, or autoimmune liver diseases.
• Non-alcoholic fatty liver disease is also a consideration in psoriatic patients.

Conclusions:

• Effective management of psoriasis requires careful consideration of potential drug-induced liver toxicity.
• Early identification and management of liver dysfunction are crucial for patient safety.
• This review aids clinicians in navigating the complexities of treating psoriatic patients with compromised liver function.